An advanced computational model enables scientists to study how cancer cells navigate through blood vessels.
List view / Grid view
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
A certain macrophage phenotype is more effective than another phenotype commonly used in cell therapy for infiltrating tumours.
Using the nicotinamide mononucleotide molecule led to proliferation of non-senescent macrophages and lessened immunosuppressive factors.
Protein released by C. burnetti interacts with antioxidising enzyme GPX4 to prevent cell damage and death.
Cell therapies hold great potential for treating complex diseases, yet they face significant limitations and challenges. Current cell therapies have difficulty distinguishing between healthy and cancerous cells, often resulting in adverse effects. Vittoria's innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of…
A $1.2 million grant has been given to observe how Z-RNA is formed and explore its benefits for various diseases.
Dr Rob van Montfort, a leading researcher at the Centre for Cancer Drug Discovery (CCDD) within The Institute of Cancer Research, London, is at the forefront of cancer drug discovery. Focusing on protein-ligand interactions, his work utilises structural biology and biochemical methods to help the discovery of novel small-molecule drugs…
Researchers have developed a new bioreactor that can manufacture T cells faster than other technologies, which may advance immunotherapy.